hVIVO signs £2.5m contract for Omicron characterisation study

hVIVO plc (LON:HVO), a fast growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed a £2.5m contract with a mid-sized pharmaceutical company to initiate an Omicron characterisation study. The manufacture of hVIVO’s Omicron BA.5 challenge agent was successfully completed in 2023.

Highlights

Characterisation study to establish world’s first Omicron BA.5 challenge model
Study to utilise hVIVO’s new state-of-the-art containment level 3 (CL3) quarantine facilities in Canary Wharf
FluCamp to recruit healthy 18-30 year old seropositive volunteers who have previously completed a course of COVID-19 vaccination
New quarantine unit in Canary Wharf facilitates the expansion of hVIVO’s world leading portfolio of human challenge models
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO fast-tracks drug trials and draws big pharma in

    In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight pharmaceutical partners along the way. hVIVO